"Ozempic face": what it is, and where the weight comes from

Reviewed 18 sourcesPublished by PepVault

"Ozempic face" is the face losing fat with the body. What the trials' scans show about where GLP-1 weight comes from, and the one study that measured faces.

A laughing man in a rust knit polo in a garden
Last reviewed
Sources
18
Questions
8
Compounds
2

The short answer

"Ozempic face" is a nickname, not a diagnosis: a hollower, looser-looking face after a large weight loss. In the trials' body scans, about two-thirds to three-quarters of the weight lost on a GLP-1 was fat, and the face loses fat with the body. The one study that measured faces on the drug found about 7% less midface volume per 10 kg lost. Surgery and diets do the same.

Every number checked at its primary source · · 18 sources · How we research

Evidence: Body composition from DXA substudies of two phase 3 randomised trials (STEP 1, SURMOUNT-1); the face from one retrospective imaging study of 20 people on a GLP-1, bariatric cohort studies and a systematic review, an MRI substudy of a diet trial, twin studies, patient surveys, one preprint, a small tissue study and reviews. No randomised trial has measured the face on a GLP-1.

A laughing man in a rust knit polo in a garden

What is "Ozempic face"?

It is a social-media name for the face changing during a big weight loss on a GLP-1 drug: hollower cheeks, deeper folds around the mouth, looser skin along the jaw, and an older look. It is not a medical diagnosis, and the reviews that study it point out that the name implies a drug-specific side effect when the same changes follow other large weight losses12. A 2025 review found that searches for the term rose alongside searches for face filler and plastic surgeons3.

The plain mechanism is the weight loss itself. The face holds fat in pads under the skin, like the rest of the body. When body fat falls, those pads shrink, and skin that was stretched over them has less underneath it1. Ozempic is semaglutide, a GLP-1 receptor agonist: a copy of a gut hormone that turns appetite down. Mounjaro and Zepbound are tirzepatide, which acts on GLP-1 and a second gut-hormone receptor, GIP.

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

In PepVault, the Body page logs your weight and keeps face check-ins (one dated front photo each), and can set any two check-ins side by side.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where does the weight come from on a GLP-1?

Mostly fat. Two of the main obesity trials scanned a subgroup with DXA, a low-dose X-ray scan that splits the body into fat, bone and lean mass (muscle, organs and water). In STEP 1, the 83 scanned people on semaglutide 2.4 mg lost 9.3 kg of fat and 5.8 kg of lean mass over 68 weeks4. In SURMOUNT-1, the 124 scanned people on tirzepatide lost 33.9% of their fat mass and 10.9% of lean mass over 72 weeks, and about 75% of the weight lost was fat5.

Trial (DXA group)WeeksFat lostLean mass lostFat share of the loss
STEP 1, semaglutide 2.4 mg (83 people)689.3 kg5.8 kgAbout 62%4
SURMOUNT-1, tirzepatide 5 to 15 mg (124 people)7233.9% of fat mass10.9% of lean massAbout 75%5
SURMOUNT-1, placebo with diet advice (36 people)728.2% of fat mass2.6% of lean massAbout 75%5
The weight lost split into fat and lean: semaglutide in STEP 1 about 62% fat, tirzepatide in SURMOUNT-1 about 75%, and SURMOUNT-1’s placebo with diet advice also about 75%
Look at the placebo bar: diet alone lost weight in the same three-to-one split as tirzepatide.

The placebo row is the useful one. People in SURMOUNT-1 who took no drug and lost weight on diet and activity advice lost it in the same 75-to-25 split as people on tirzepatide; they simply lost less5. In this trial, the drug changed how much weight came off, not what it was made of. Neither trial scanned the face: DXA reports the whole body and its main regions.

STEP 1's share is worked out from the trial's own kilogram results (9.3 kg of fat out of 15.1 kg of fat and lean mass). The trials ran in different people for different lengths of time, so the two drugs' shares are not a head-to-head comparison. STEP 1's placebo group (39 people) lost about 3 kg in all, too little to read a split from4.

Has any study measured the face on a GLP-1?

One study has measured how the face itself changes on a GLP-1, as of November 2026. At Vanderbilt University Medical Center, surgeons searched the hospital's records for people with a GLP-1 prescription and a head or neck CT or MRI scan from both before and after they started, and measured the midface (the cheeks, between the eyes and the mouth) on each scan6. Twenty people qualified, with a median age of 54. They had been on the drug for about 321 days on average and had lost 11.0 kg6.

  • Total midface volume fell by a median of 9%6.
  • The shallow fat layer just under the skin fell 11%, the deeper layer 7%6.
  • The more weight a person lost, the more of the shallow layer went; the deep layer did not track weight loss6.
  • Across the group, the face lost about 7% of its midface volume for every 10 kg of body weight lost6.
Two fat layers of the midface on the bone, before and after: the shallow layer under the skin 11% thinner, the deep layer on the bone 7% thinner
The shallow fat layer under the skin shrank more than the deep one, and it is the layer that tracked weight loss.

It is a small study of scans already in people's records, with no group of people losing the same weight without the drug, so it shows how much the face changes with the weight, not whether the drug adds anything of its own6. No randomised trial of a GLP-1 drug has measured the face; the controlled studies registered so far test a face treatment in people already on one, and none has reported. A questionnaire for rating your own face on a GLP-1, a short form of the FACE-Q scale, was validated in 2026 in 632 people considering, taking or past one, so future trials have a tool to ask18.

Does the same thing happen after bariatric surgery or a diet?

Yes, and it was described long before the name. A 2023 systematic review of four studies, 129 people after bariatric surgery, found facial sagging alongside the weight loss, and judged the evidence still thin7. In Germany, 3D face scans of 23 people before and six months after surgery showed the distances from the ear to the chin shrinking and the neck losing about 75 mL of volume on average, and the neck's loss did not line up with total weight lost8.

Diet alone does it too. In the CENTRAL trial, 278 adults with abdominal obesity, mostly men, were put on low-fat or Mediterranean low-carb diets and followed for 18 months with whole-body MRI. After six months the fat under the skin of the neck had fallen 13.1% and under the chin 5.3%, and the 18-month changes tracked weight loss9.

How the face reads depends on more than the fat. In a Boston study, survey respondents rated photos of 14 people before and after bariatric surgery: overall they looked more attractive afterwards, while only five changed significantly in perceived age, three looking older and two younger10.

Is it the drug or the weight loss?

The weight loss, on the evidence so far. A 2026 review of 46 reports concluded that the changes are best explained as weight-loss deflation laid over a person's own anatomy and age, the same picture seen after surgery, and that the role of how fast the weight comes off is still unknown1.

Two early studies keep the question open. A records study of women with diabetes and high blood pressure, posted as a preprint and not yet peer-reviewed, found upper-eyelid surgery about twice as common over five years in GLP-1 users as in matched non-users (0.41% against 0.15% of women; hazard ratio 2.22), while weight loss without the drug showed no clear link11. And in 10 tissue samples of belly fat, people on a GLP-1 had about a quarter as many fat-tissue stem cells as untreated controls12. Neither measured a face, and neither shows a drug effect on facial fat.

Who notices it most?

Older people and those who lose the most. In a US survey of 504 adults on a GLP-1 drug, tirzepatide included, mostly women with an average age of 53 and run by a cosmetics company's research team, 10.9% reported facial volume loss, 8.3% sagging and 7.7% jowls; skin changes were linked to being over 55 and to losing more than 20 lb (9.1 kg)13. In a second survey of 1,226 telemedicine patients, concerns such as facial volume loss rose with the amount of weight lost14.

Age changes what fat does for the face. In a study of 186 pairs of identical twins, the heavier twin looked older below age 40 and younger above it, for a four-point difference in BMI (body mass index)15. Among Danish twins over 70, a low BMI went with looking older16. Facial fat reads as youth later in life, which fits the surveys and reviews finding the change most visible in older people113.

Commonly reported: noticing it first in photos rather than the mirror, cheeks and temples going first, friends commenting on looking tired while the scale is going the right way, and the face settling once weight holds steady. In the survey of 504 users, 92% were satisfied with their treatment and 84% reported a better body image13.

What does the dermatology literature describe for it?

Mostly volume and skin treatments borrowed from post-weight-loss care: fillers, collagen-stimulating injectables, radiofrequency devices and topical products17. A 2026 systematic review found four studies of them in facial change after weight loss, two in GLP-1 users only, 98 treated people in all, none with a comparison group, and concluded the evidence is too preliminary to say what works best17. This is a description of the literature, not a recommendation, and whether to treat a change in appearance at all is a choice for you and a dermatologist.

What the evidence does support is that facial fat tends to follow body fat. The weight change is the thing that moves the face, which is why the change shows up with every method of losing a lot of weight179.

How do you track how your face is changing?

Mirrors and casual selfies mislead: light, angle and the lens's distance all change how full a face looks. Comparable photos and a weight log show whether the face is following the scale.

  1. Stand facing a window at the same time of day, so the light falls the same way every time.
  2. Hold the phone at eye level, at arm's length, with your face straight on and a neutral expression.
  3. Take one photo before your first dose (or today, if you have started), then one every four weeks on the same day you weigh in.
  4. Compare each photo with the first, not with last week's, alongside the weight you lost in between.

In PepVault, the Body page logs your weight and keeps face check-ins (one dated front photo each), and can set any two check-ins side by side. Track your weight in PepVault

When to get help If the weight is coming off much faster than your plan, or you are eating so little that you feel weak or dizzy, tell your prescriber.

Track it in the app

Sources

  1. Yoo KH. Glucagon-like peptide-1 receptor agonist-associated facial changes: a comprehensive review of pathophysiology, clinical manifestations, risk factors, prevention, and management. Aesthet Surg J. 2026 (online ahead of print). PubMed 42872378
  2. Carboni A, Woessner S, Martini O, Marroquin NA, Waller J. Natural weight loss or "Ozempic face": demystifying a social media phenomenon. J Drugs Dermatol. 2024;23(1):1367-1368. PubMed 38206146
  3. Daneshgaran G, Shauly O, Gould DJ. "Ozempic face" in plastic surgery: a systematic review of the literature on GLP-1 receptor agonist mediated weight loss and analysis of public perceptions. Aesthet Surg J Open Forum. 2025;7:ojaf056. PubMed 40626110
  4. Novo Nordisk A/S. STEP 1: semaglutide 2.4 mg in adults with overweight or obesity (NCT03548935). ClinicalTrials.gov results: change in total fat mass and lean body mass (kg) by DXA, week 0 to 68. clinicaltrials.gov
  5. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. PubMed 39996356
  6. Sharma RK, Vittetoe KL, Barna AJ, et al. Radiographic midfacial volume changes in patients on GLP-1 agonists. Otolaryngol Head Neck Surg. 2025;173(2):360-366. PubMed 40407186
  7. Wong ZY, Ramasamy P, Ingels KJAO, et al. Changes of facial features after bariatric surgery: a systematic review. Obes Surg. 2023;33(1):332-338. PubMed 36434358
  8. Peters F, Kroh A, Neumann UP, et al. Morphological changes of the human face after massive weight-loss due to bariatric surgery. J Craniomaxillofac Surg. 2020;48(7):694-699. PubMed 32513431
  9. Tsaban G, Bilitzky-Kopit A, Yaskolka Meir A, et al. The effect of weight-loss interventions on cervical and chin subcutaneous fat depots; the CENTRAL randomized controlled trial. Nutrients. 2021;13(11):3827. PubMed 34836081
  10. Papoian V, Mardirossian V, Hess DT, Spiegel JH. Effects of bariatric surgery on facial features. Arch Plast Surg. 2015;42(5):567-571. PubMed 26430627
  11. Almeida VFA, Ha J, Duraes F, et al. Use of GLP-1 receptor agonists is associated with an increased rate of upper eyelid blepharoplasty. Res Sq [preprint, not peer-reviewed]. 2026. PubMed 42245794
  12. Firsowicz M, Kamrani P, Zubair R, et al. Cutaneous variations in stem-cell population in those on GLP1-receptor agonists: a comparative controlled study. Dermatol Surg. 2026;52(6S):S39-S44. PubMed 42210886
  13. Olivero JW, Paturi J, Moreau M, et al. Dermatological, trichological and quality of life consequences of GLP-1 receptor agonist-mediated weight loss: a US cross-sectional survey. J Cosmet Dermatol. 2026;25(8):e71145. PubMed 43047060
  14. Santiago Mangual KP, Midura I, Patin E, et al. Aesthetic, muscle, and dermatologic effects of medical weight management: patient-reported outcomes shape a holistic preventive procedural approach. Int J Womens Dermatol. 2026;12(3):e283. PubMed 42639588
  15. Guyuron B, Rowe DJ, Weinfeld AB, et al. Factors contributing to the facial aging of identical twins. Plast Reconstr Surg. 2009;123(4):1321-1331. PubMed 19337100
  16. Rexbye H, Petersen I, Johansens M, et al. Influence of environmental factors on facial ageing. Age Ageing. 2006;35(2):110-115. PubMed 16407433
  17. Maglitto F, Salzano G, Trotta S, et al. Beyond weight loss: facial remodeling associated with GLP-1 receptor agonists. A systematic review and therapeutic framework. Aesthetic Plast Surg. 2026 (online ahead of print). PubMed 42864543
  18. Klassen AF, Gallo L, Dayan S, et al. Measuring facial appearance in GLP-1 agonist use with the FACE-Q Aesthetics item library. Aesthet Surg J. 2026 (online ahead of print). PubMed 42140744

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo